{"filing":{"accession_number":"0001193125-26-267485","cik":"0001807120","ticker":"DSGN","company_name":"Design Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"dsgn-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526267485/dsgn-20260609.htm"},"events":[{"id":5351,"run_id":4688,"accession_number":"0001193125-26-267485","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Design Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of director Simeon George, M.D. as a Class II director with 29,205,208 votes for and 7,608,724 withheld, and (2) ratification of Ernst \u0026 Young LLP as independent auditor with 50,077,708 votes for and minimal opposition. These are routine but material shareholder governance matters.","company_name":"Design Therapeutics, Inc.","ticker":"DSGN","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6233,"accession_number":"0001193125-26-267485","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Design Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of director Simeon George, M.D. as a Class II director with 29,205,208 votes for and 7,608,724 withheld, and (2) ratification of Ernst \u0026 Young LLP as independent auditor with 50,077,708 votes for and minimal opposition. These are routine but material shareholder governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:06:12.046507+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6233,"accession_number":"0001193125-26-267485","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Design Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of director Simeon George, M.D. as a Class II director with 29,205,208 votes for and 7,608,724 withheld, and (2) ratification of Ernst \u0026 Young LLP as independent auditor with 50,077,708 votes for and minimal opposition. These are routine but material shareholder governance matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:06:12.046507+00:00","company_name":"Design Therapeutics, Inc.","ticker":"DSGN","filing_date":"2026-06-11"}]}